Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

• Published in: Clinical cancer research Vol. 26; no. 8; pp. 2037 - 2046
• Main Authors: Isomoto, Kohsuke, Haratani, Koji, Hayashi, Hidetoshi, Shimizu, Shigeki, Tomida, Shuta, Niwa, Takashi, Yokoyama, Toshihide, Fukuda, Yasushi, Chiba, Yasutaka, Kato, Ryoji, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Ogura, Takashi, Ishida, Tadashi, Ito, Akihiko, Nakagawa, Kazuhiko
• Format: Journal Article
• Language: English
• Published: United States 15.04.2020
• Subjects: Adult; Aged; Aged, 80 and over; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - metabolism; Biomarkers, Tumor - immunology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - pathology; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Female; Humans; Immune Checkpoint Inhibitors - therapeutic use; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lymphocytes, Tumor-Infiltrating - immunology; Male; Middle Aged; Mutation; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology

The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non-small cell lung cancer (NSCLC) is unclear. We retrospectively identified 138 patients with -mutated NSCLC who underwent rebiopsy after progression during EGFR-TKI treatment. PD-L1 and CD73 expressio...